Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers

Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024.

The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease progression among patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction cancers reported from Chinese investigators.

The first author of the report, Jiafu Ji, MD, PhD, DrPH, FACS, FRCS, Fellow of the Chinese Academy of Medical Science, as well as Professor and Chief of the Gastrointestinal Cancer Center at Peking University Cancer Hospital and the Beijing Institute for Cancer Research in China, called into the Oncology Times office at AACR after his talk to discuss his team’s findings with Peter Goodwin, an OncTimesTalk correspondent.